Biodesix
Biodesix Q2 Revenues Shoot up but Fall Short of Wall Street Expectations
COVID-19 testing revenues grew to $6.0 million while lung diagnostic revenues rose to $4.8 million and biopharma revenues increased to $1.0 million.
Biodesix, Datavant Join in Lung Cancer Data Partnership
Datavant will anonymize lung cancer records from the Biodesix biobank and add real-world data to aid researchers and biopharma companies.
Biodesix Q1 Revenues Soar on COVID-19 Testing
For the three months ended March 31, the firm reported revenues of $28.9 million, compared to $5.1 million in the same period a year ago.
The firm will commercialize its Primary Immune Response assay as a laboratory-developed test to help guide immunotherapy decisions in lung cancer patients.
Biodesix Secures $30M Term Loan
The firm used the proceeds to repay outstanding borrowings of $25.9 million under its existing loan with Innovatus Life Sciences Lending Fund.
Dec 11, 2020
Biodesix Q3 Revenues Rise Sharply
Nov 23, 2020
Three Investment Banks Initiate Coverage of Biodesix
Oct 28, 2020
Biodesix Prices $72M IPO
Aug 17, 2020
Mar 20, 2020
Biodesix, Bio-Rad Partner on Coronavirus Test
Jul 10, 2018
Jul 9, 2018
Biodesix Acquires Integrated Diagnostics
Mar 5, 2018
Biodesix Inks $23M Debt Refinancing
Dec 14, 2017
Nov 17, 2017